- Home
- VNDA vs CMPS Comparison
VNDA vs CMPS Comparison
Compare VNDA & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- CMPS
- Stock Information
- Founded
- VNDA 2002
- CMPS 2020
- Country
- VNDA United States
- CMPS United Kingdom
- Employees
- VNDA N/A
- CMPS N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- CMPS Health Care
- Exchange
- VNDA Nasdaq
- CMPS Nasdaq
- Market Cap
- VNDA 270.0M
- CMPS 280.2M
- IPO Year
- VNDA 2006
- CMPS 2020
- Fundamental
- Price
- VNDA $4.77
- CMPS $4.00
- Analyst Decision
- VNDA Strong Buy
- CMPS Strong Buy
- Analyst Count
- VNDA 2
- CMPS 6
- Target Price
- VNDA $15.50
- CMPS $33.60
- AVG Volume (30 Days)
- VNDA 704.2K
- CMPS 705.9K
- Earning Date
- VNDA 02-05-2025
- CMPS 10-31-2024
- Dividend Yield
- VNDA N/A
- CMPS N/A
- EPS Growth
- VNDA N/A
- CMPS N/A
- EPS
- VNDA N/A
- CMPS N/A
- Revenue
- VNDA $190,858,000.00
- CMPS N/A
- Revenue This Year
- VNDA $5.60
- CMPS N/A
- Revenue Next Year
- VNDA $42.85
- CMPS N/A
- P/E Ratio
- VNDA N/A
- CMPS N/A
- Revenue Growth
- VNDA N/A
- CMPS N/A
- 52 Week Low
- VNDA $3.46
- CMPS $3.86
- 52 Week High
- VNDA $6.75
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- VNDA 42.69
- CMPS 37.40
- Support Level
- VNDA $4.49
- CMPS $3.86
- Resistance Level
- VNDA $4.81
- CMPS $4.91
- Average True Range (ATR)
- VNDA 0.18
- CMPS 0.28
- MACD
- VNDA -0.03
- CMPS -0.01
- Stochastic Oscillator
- VNDA 25.71
- CMPS 16.59
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.